Takeda And Halozyme Enter Global Collaboration To Enhance Vedolizumab With ENHANZE® Technology For ENTYVIO® Expansion

Takeda has entered into a global collaboration and licensing agreement with Halozyme Therapeutics to access Halozyme’s ENHANZE® drug delivery technology for use with vedolizumab. The agreement grants Takeda exclusive rights to apply the technology to its gastrointestinal biologic, marketed as ENTYVIO®, reinforcing the company’s commitment to advancing care for patients with inflammatory bowel disease (IBD).

Ulcerative colitis and Crohn’s disease are chronic, complex conditions that often require long-term and evolving treatment strategies. With the global prevalence of IBD expected to exceed 10 million patients by 2032, Takeda aims to continue innovating within its GI and inflammation portfolio. The collaboration is intended to expand the potential of vedolizumab and support broader global access to treatment options for patients living with IBD.

“For more than a decade, vedolizumab has played a pivotal role in helping patients to manage ulcerative colitis and Crohn’s disease. This collaboration marks another significant step in our dedication and leadership within the IBD community, including relentless pursuit of research and development addressing important patient needs,” said Robert Hollowell, M.D., Head of Global Product and Launch Strategy, GI and Inflammation at Takeda. “By integrating ENHANZE technology, we aim to offer greater flexibility in vedolizumab treatment, improve patient experience, and continue our focus on high-impact partnerships that deliver value for patients, health care providers, and the broader healthcare community.”

Under the terms of the agreement, Takeda will make an upfront payment to Halozyme and may provide additional development and commercial milestone payments in the future. Halozyme will also receive royalties on sales of vedolizumab products that incorporate the ENHANZE® technology. The partnership underscores the strategic value of Halozyme’s drug delivery platform, which has been utilized in multiple commercial products worldwide.

Dr. Helen Torley, President and Chief Executive Officer of Halozyme, added: “Our partnership with Takeda demonstrates our ongoing commitment to delivering innovative solutions that improve the patient experience. By leveraging ENHANZE, a commercially validated solution that facilitates the subcutaneous delivery of injected drugs, we aim to help patients spend less time managing their therapy and more time living their lives. This collaboration further highlights the broad applicability and value of ENHANZE across multiple therapeutic areas.”

ENHANZE® is based on Halozyme’s proprietary recombinant human hyaluronidase PH20 (rHuPH20) enzyme and has supported more than one million patient experiences across over 100 global markets. Vedolizumab, available in both intravenous and subcutaneous formulations depending on region, is approved in more than 70 countries for IV use and over 50 countries for SC use, with more than one million patient-years of exposure globally to date.